Skip to main content

Advertisement

SpringerLink
Log in

Could co-payments on drugs help to make EU health care systems less open to political influence?

  • Editorial
  • Published:
The European Journal of Health Economics Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Drummond, M., Towse, A.: Is it time to reconsider the role of patient co-payments for pharmaceuticals in Europe? Eur. J. Health Econ. 13(1), 1–5 (2012)

    Article  PubMed  Google Scholar 

  2. Gemmill, M., Thomson, S., Mossialos, E.: What impact do prescription drug charges have on efficiency and equity? Evidence from high-income countries. Int. J. Equity Health. 2(7), 12 (2008)

    Article  Google Scholar 

  3. Trivedi, A.N., Moloo, H., Mor, V.: Increased ambulatory care copayments and hospitalizations among the elderly. N. Engl. J. Med. 362(4), 320–328 (2010)

    Article  CAS  PubMed  Google Scholar 

  4. Freemantle, N., Bloor, K.: Lessons from international experience in controlling pharmaceutical expenditure I: influencing patients. BMJ 312(7044), 1469–1471 (1996)

    Article  CAS  PubMed  Google Scholar 

  5. Giuliani, G., Selke, G., Garattini, L.: The German experience in reference pricing. Health Policy 44(1), 73–85 (1998)

    Article  CAS  PubMed  Google Scholar 

  6. Chevreul, K., Durand-Zaleski, I., Bahrami, S., et al.: France: health system review. Health Syst. Transit. 12(6), 1–291 (2010)

    PubMed  Google Scholar 

  7. Zuzahlungsregelungen ab 1.1.2004. http://www.zuzahlung.de/. Accessed 6 July 2012

  8. Boletín oficial del estado. http://www.boe.es/boe/dias/2012/04/24/pdfs/BOE-A-2012-5403.pdf

  9. NHS. Prescription costs. http://www.nhs.uk/NHSEngland/Healthcosts/Pages/Prescriptioncosts.aspx. Accessed 6 July 2012

  10. Fiorio, C., Siciliani, L.: Co-payments and the demand for pharmaceuticals: evidence from Italy. Econ. Model. 27(4), 835–841 (2010)

    Article  Google Scholar 

  11. Federfarma. Farmaci e farmacie > Ticket regionali 11/05/12. http://www.federfarma.it/Farmaci-e-farmacie/Ticket-Regionali.aspx. Accessed 6 July 2012

  12. Parlament de Catalunya. Ley 5/2012. http://www.parlamenta.es/legislacion/parlament-de-catalunya/ley/tasa-turistica-y-copago-farmaceutico-de-un-euro-por-receta. Accessed 6 July 2012

  13. Rijksoverheid. Zorgverzekering. http://www.rijksoverheid.nl/onderwerpen/zorgverzekering/vraag-en-antwoord/wat-is-het-eigen-risico-in-de-zorgverzekering.html. Accessed 6 July 2012

  14. CAK. Compensatie verplicht eigen risico 2012. http://www.hetcak.nl/portalserver/portals/cak-portal/pages/k1-3-0-1-compensatie-eigen-risico-2012. Accessed 6 July 2012

  15. Galizzi, M.M., Ghislandi, S., Miraldo, M.: Effects of reference pricing in pharmaceutical markets: a review. Pharmacoeconomics 29(1), 17–33 (2011)

    Article  PubMed  Google Scholar 

  16. Drummond, M., Jonsson, B., Rutten, F., et al.: Reimbursement of pharmaceuticals: reference pricing versus health technology assessment. Eur. J. Health Econ. 12(3), 263–271 (2011)

    Article  PubMed  Google Scholar 

  17. Dalla padella alla brace. Diaologo sui farmaci. 5 (2011). http://www.dialogosuifarmaci.it/rivista/pdf/4ec15936a163e.pdf. Accessed 6 July 2012

  18. Vogler, S., Espin, J., Habl, C.: Pharmaceutical pricing and reimbursement information (PPRI)—New PPRI analysis including Spain. Pharm. Policy Law 11, 213–234 (2009)

    Google Scholar 

  19. Garattini, L., Ghislandi, S.: Off-patent drugs in Italy. A short-sighted view? Eur. J. Health Econ. 7(1), 79–83 (2006)

    Article  PubMed  Google Scholar 

  20. Stargardt, T.: The impact of reference pricing on switching behaviour and healthcare utilisation: the case of statins in Germany. Eur. J. Health Econ. 11(3), 267–277 (2010)

    Article  PubMed  Google Scholar 

  21. Garattini, L., Van de Vooren, K.: Ethics for end-of-life treatments: metastatic colorectal cancer is one example. Health Policy (2012) (in press)

  22. Colombo, C., Mosconi, P., Villani, W., et al.: Patient organizations’ funding from pharmaceutical companies: is disclosure clear, complete and accessible to the public? An Italian survey. PLoS ONE 7, e34974 (2012)

    Article  CAS  PubMed  Google Scholar 

  23. Richards, M.: A report for the Secretary of State for Health. Improving access to medicines for NHS patients. November 2008. http://www.dh.gov.uk/dr_consum_dh/groups/dh_digitalassets/@dh/@en/documents/digitalasset/dh_089952.pdf. Accessed 6 July 2012

  24. Garattini, L., Van de Vooren, K.: HPV vaccination for boys? Talking economic sense. J. Sex. Med. Jul 3 (2012). doi: 10.1111/j.1743-6109.2012.02828.x. (Epub ahead of print)

Download references

Author information

Authors and Affiliations

  1. ‘Mario Negri’ Institute for Pharmacological Research, CESAV (Centre for Health Economics), Ranica, Italy

    Livio Garattini & Katelijne van de Vooren

Authors
  1. Livio Garattini
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Katelijne van de Vooren
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Livio Garattini.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Garattini, L., van de Vooren, K. Could co-payments on drugs help to make EU health care systems less open to political influence?. Eur J Health Econ 14, 709–713 (2013). https://doi.org/10.1007/s10198-012-0428-1

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10198-012-0428-1

Search

Navigation